BAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Braskem SA (BAK) is not a good buy for a beginner, long-term investor at this time. Despite some positive technical indicators, the company's financials are weak, analysts have mixed views, and there are no strong positive catalysts to justify an investment. The stock also has a high probability of declining in the short term, making it unsuitable for this investor's profile.
The technical indicators show mixed signals. The MACD is positive and contracting, which is slightly bullish. The RSI is neutral at 47.939, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level of 3.785, with resistance at 4.186 and support at 3.384. Short-term stock trend analysis indicates a 60% chance of declining in the next day (-3.62%), week (-10.64%), and month (-6.67%).
Citi recently upgraded the stock to Neutral from Sell, citing higher petrochemical prices that could improve cash flow and leverage.
BofA downgraded the stock to Underperform, citing liquidity concerns, persistent cash burn, and a significant debt maturity of $383M this year. The company's financial performance in Q4 2025 was weak, with a revenue decline of -9.09% YoY and a gross margin drop of -157.26% YoY. Additionally, there is no recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, Braskem's revenue dropped by -9.09% YoY to $2.98B. Net income improved but remained negative at -$1.90B (up 96.95% YoY). EPS also improved but was still negative at -2.39 (up 97.52% YoY). Gross margin fell significantly to -3.43%, down -157.26% YoY, indicating poor profitability.
Analyst ratings are mixed. Citi upgraded the stock to Neutral with a price target of R$10, citing potential improvements in cash flow. However, BofA downgraded it to Underperform with a price target of $2.80, citing liquidity concerns and tight petrochemical spreads.
